Results 41 to 50 of about 28,830 (241)

Nose to brain delivery of Efavirenz nanosuspension for effective neuro AIDS therapy: in-vitro, in-vivo and pharmacokinetic assessment

Heliyon, 2021
Efavirenz is inhibitor of non-nucleoside reverse transcriptase enzyme; BCS class II drug. The objective of the present research was to prepare and evaluate nanosuspension of Efavirenz for the treatment of neuro-AIDS.
Smita Kakad, Sanjay Kshirsagar
doaj   +1 more source

Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

Angewandte Chemie International Edition, EarlyView.
Understanding stereoselective biotransformations has implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in metabolite and API synthesis. ABSTRACT Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different ...
Grace A. Okunlola, Godwin A. Aleku
wiley   +1 more source

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections

Universa Medicina, 2016
The increased percentage of patients with HIV-TB coinfection leads to inevitable interactions between rifampicin and efavirenz. Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection.
Yenny Yenny
doaj   +1 more source

Effect of ABCB1 3435C>T transporter gene polymorphism on plasma efavirenz concentration in HIV-1 infected Thai adults

Asian Pacific Journal of Tropical Medicine, 2020
Objective: To investigate the influence of ABCB1 polymorphisms on the plasma level of efavirenz in Thai adult cases infected with HIV-1. Methods: A single nucleotide polymorphism of ABCB1 3435C>T (rs1045642) in the gene encoding ABCB1 was genotyped using
Sahapat Barusrux, Napatrupron Koomdee, Rattanaporn Sukprasong, Weerawat Manosuthi, Monpat Chamnanphon, Apichaya Puangpetch, Chonlaphat Sukasem, Veeranoot Nissapatorn, Maria de Lourdes Pereira   +8 more
doaj   +1 more source

The long-term effectiveness of efavirenz-based combination antiretroviral therapy, the impact of pharmacogenomics and pharmacokinetic interaction of artemisinin-based antimalarial therapy on efavirenz exposure among Ghanaian HIV-infected patients [PDF]

, 2013
Dr. Fred Stephen Sarfo, The long-term effectiveness of efavirenz-based combination antiretroviral therapy, the impact of pharmacogenomics and pharmacokinetic interaction of artemisinin-based antimalarial therapy on efavirenz exposure among Ghanaian HIV ...
SARFO, FRED,STEPHEN
core  

A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads

, 2006
Background. Our objective was to compare the rate of viral rebound and therapy failure in patients receiving abacavir or efavirenz as the third drug ( in addition to 2 non-abacavir nucleosides) in combination antiretroviral therapy ( cART) and to compare
Phillips, AN, L. Sighinolfi, D'ARMINIO MONFORTE A, R. Cauda, MOIOLI MC, Monforte, AD, COZZI-LEPRI A, DI GIAMBENEDETTO S, M. Mena, Sighinolfi, L, SIGHINOLFI L, A. Cozzi Lepri, Lichtner, M, ICoNA Study Group, Arlotti, M, M. Lichtner, Bongiovanni, M, Mena, M, M. Arlotti, UCSC Roma HIV Cohort Study Group, CAUDA R, A. N. Phillips, De Luca, A, Di Giambenedetto, S, Cozzi-Lepri, A, DE LUCA A, BONGIOVANNI M, PHILLIPS AN, UCSC-Roma HIV Cohort Study Grp, Narciso, P, Cauda, R, IMIT Study Grp, IMIT Study Group, A. De Luca, ICoNA Study Grp, MENA M, ARLOTTI M, NARCISO P, LICHTNER M, M. C. Moioli, Moioli, MC, S. Di Giambenedetto, P. Narciso, M. Bongiovanni, A. d’Arminio Monforte   +44 more
core   +1 more source

Shedding Light on Synthetic Autocatalysis: From Conventional Closed‐Shell Chemistries to Overlooked Open‐Shell Occurrences

Chemistry – A European Journal, EarlyView.
Why add another catalyst when the product itself holds the power to catalyze its own formation? Autocatalysis in synthetic chemistry enhances reaction efficiency and uncovers novel catalytic behavior across both closed‐shell and open‐shell systems, expanding reactivity and enabling innovative design strategies.
Jaspreet Kaur, Joshua P. Barham
wiley   +1 more source

Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation

, 2016
Adequate concentrations of efavirenz in the central nervous system (CNS) are necessary to suppress viral replication, but high concentrations may increase the likelihood of CNS adverse drug reactions.

core   +1 more source

HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications. [PDF]

, 2019
BACKGROUND The HIV drugs lopinavir and ritonavir have recently been reported to cause transient adrenal insufficiency in preterm newborns. We, therefore, considered HIV drugs as a cause of transiently elevated 17-hydroxyprogesterone (17OHP) levels in ...
Brixius-Anderko, Simone, McDougall, Jane, Sluka, Susanna; https://orcid.org/, Malikova, Jana, Pandey, Amit V; https://orcid.org/, Zingg, Tanja, Sluka, Susanna, Flück, Christa Emma, Pandey, Amit Vikram, Fingerhut, Ralph, Grössl, Michael, Flück, Christa E, Bernhardt, Rita   +12 more
core   +1 more source

A Non‐Antigenic Randomized Polyethylene Glycol/Poly(2‐Phenyl‐2‐Oxazine)‐Based Drug Delivery Platform

Macromolecular Rapid Communications, EarlyView.
Randomized PEG (rPEG), a conceptually new PEG alternative, is combined with poly(2‐phenyl‐2‐oxazine) (PPheOzi) to establish an rPEG‐b‐PPheOzi‐b‐rPEG micellar drug delivery platform. The PPheOzi block enables high drug loadings, while competitive ELISA reveals a drastic reduction in anti‐PEG antibody affinity of rPEG in comparison to PEG.
Julian Schmidt, Anna‐Lena Ziegler, Florian T. Kaps, Laura J. Rosenberger, Matthias Bros, Holger Frey, Robert Luxenhofer   +6 more
wiley   +1 more source